SCHEMBL2686770

SCHEMBL2686770

Cc1nc2cc(-c3nc4ccccc4o3)ccc2n1-c1ccccc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPK1 P28482 2/20 0.55
▸ HTT P42858 1/20 0.55
▸ ALDH1A1 P00352 6/20 0.54
▸ HSD17B10 Q99714 3/20 0.51
▸ NPC1 O15118 7/20 0.49
▸ KDM4E B2RXH2 6/20 0.49
▸ SMN1; SMN2 Q16637 5/20 0.49
▸ HPGD P15428 5/20 0.49
▸ RAB9A P51151 5/20 0.49
▸ HCRTR1 O43613 2/20 0.49
▸ NFKB1 P19838 1/20 0.49
▸ STAT1 P42224 1/20 0.49
▸ NFKB2 Q00653 1/20 0.49
▸ RELA Q04206 1/20 0.49
▸ USP2 O75604 2/20 0.48
▸ MAPT P10636 2/20 0.48
▸ TSHR P16473 1/20 0.48
▸ CASP3 P42574 1/20 0.48
▸ NPSR1 Q6W5P4 1/20 0.48
▸ SENP8 Q96LD8 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2687352 0.91 NPC1 (0.46) MAPK1HTTALDH1A1HSD17B10NPC1
SCHEMBL2689901 0.89 NPC1 (0.52) MAPK1ALDH1A1HSD17B10NPC1KDM4E
SCHEMBL2687461 0.88 THRB (0.54) MAPK1ALDH1A1HSD17B10NPC1KDM4E
SCHEMBL2688110 0.83 NPC1 (0.55) MAPK1ALDH1A1HSD17B10NPC1KDM4E
SCHEMBL22746733 0.82 NPC1 (0.52) MAPK1ALDH1A1HSD17B10NPC1KDM4E
SCHEMBL2686599 0.82 NPC1 (0.58) MAPK1ALDH1A1HSD17B10NPC1KDM4E
SCHEMBL2687383 0.80 KDM4E (0.55) MAPK1HTTALDH1A1HSD17B10NPC1
SCHEMBL2686759 0.80 NPC1 (0.49) MAPK1ALDH1A1HSD17B10NPC1KDM4E
SCHEMBL2687985 0.80 NPC1 (0.49) MAPK1ALDH1A1HSD17B10NPC1KDM4E
SCHEMBL2687478 0.80 TNF (0.58) ALDH1A1KDM4ERAB9AMAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8829035-B2 Agent for treatment or prevention of diseases associated with activity of neurotrophic factors SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2014-09-09 — — US disclosed
US-8829035-B2 Agent for treatment or prevention of diseases associated with activity of neurotrophic factors SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2014-09-09 — — US disclosed
US-8829035-B2 Agent for treatment or prevention of diseases associated with activity of neurotrophic factors SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2014-09-09 — — US disclosed
EP-2436683-B1 AGENT FOR TREATMENT OR PREVENTION OF DISEASES ASSOCIATED WITH ACTIVITY OF NEUROTROPHIC FACTORS SUMITOMO CHEMICAL CO (JP) 2014-05-14 — — EP disclosed
US-20120115856-A1 AGENT FOR TREATMENT OR PREVENTION OF DISEASES ASSOCIATED WITH ACTIVITY OF NEUROTROPHIC FACTORS SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-05-10 — — US disclosed
US-20120115856-A1 AGENT FOR TREATMENT OR PREVENTION OF DISEASES ASSOCIATED WITH ACTIVITY OF NEUROTROPHIC FACTORS SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-05-10 — — US disclosed
US-20120115856-A1 AGENT FOR TREATMENT OR PREVENTION OF DISEASES ASSOCIATED WITH ACTIVITY OF NEUROTROPHIC FACTORS SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-05-10 — — US disclosed
WO-2010137349-A1 AGENT FOR TREATMENT OR PREVENTION OF DISEASES ASSOCIATED WITH ACTIVITY OF NEUROTROPHIC FACTORS 住友化学株式会社 (JP) 2010-12-02 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120115856-A1 AGENT FOR TREATMENT OR PREVENTION OF DISEASES ASSOCIATED WITH ACTIVITY OF NEUROTROPHIC FACTORS BDNF, NGF, NTRK2 MAPK1 1717/4885HTT 398/4885ALDH1A1 1772/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback